telaprevir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Hepatitis Virus C (HVC) protease inhibitors 4173 402957-28-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • telaprevir
  • VX 950
  • incivek
  • incivo
Telaprevir is an inhibitor of the HCV NS3/4A serine protease, necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. In a biochemical assay, telaprevir inhibited the proteolytic activity of the recombinant HCV NS3 protease domain with an IC50 value of 10 nM.
  • Molecular weight: 679.86
  • Formula: C36H53N7O6
  • CLOGP: 5.39
  • LIPINSKI: 3
  • HAC: 13
  • HDO: 4
  • TPSA: 179.56
  • ALOGS: -4.28
  • ROTB: 14

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Hosey CM, Chan R, Benet LZ
S (Water solubility) 0.00 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2011 EMA Janssen-Cilag International N.V.
May 23, 2011 FDA VERTEX PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 361.50 36.19 188 2217 293242 63193375
Pancytopenia 123.36 36.19 64 2341 96869 63389748
Rash 121.88 36.19 126 2279 560745 62925872
Aplastic anaemia 103.03 36.19 30 2375 9539 63477078
Thrombocytopenia 87.31 36.19 60 2345 151097 63335520
Anal pruritus 87.29 36.19 16 2389 651 63485966
Leukopenia 60.03 36.19 37 2368 77253 63409364
Haemoglobin decreased 45.05 36.19 40 2365 145445 63341172
Extradural abscess 40.87 36.19 9 2396 928 63485689
Drug reaction with eosinophilia and systemic symptoms 39.09 36.19 21 2384 33815 63452802
Neutropenia 38.76 36.19 40 2365 174965 63311652

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 317.30 34.14 235 3603 233100 34719993
Rash 246.70 34.14 199 3639 222553 34730540
Pruritus 152.39 34.14 125 3713 141856 34811237
Depressed mood 76.86 34.14 39 3799 19278 34933815
Dry skin 74.43 34.14 45 3793 31242 34921851
Thrombocytopenia 73.70 34.14 88 3750 156159 34796934
Influenza like illness 71.60 34.14 42 3796 27592 34925501
Fatigue 53.52 34.14 122 3716 370531 34582562
Wrong dose 50.56 34.14 12 3826 587 34952506
Skin irritation 50.39 34.14 20 3818 5557 34947536
Anorectal discomfort 48.88 34.14 15 3823 1949 34951144
Leukopenia 42.74 34.14 43 3795 62813 34890280
Oral herpes 40.24 34.14 17 3821 5530 34947563
Anal pruritus 39.51 34.14 9 3829 367 34952726
Retinal exudates 38.01 34.14 10 3828 746 34952347
Porphyria non-acute 37.16 34.14 9 3829 480 34952613
Haemoglobin decreased 36.73 34.14 55 3783 120717 34832376
Retinopathy 35.88 34.14 12 3826 2052 34951041
Nausea 35.41 34.14 99 3739 339809 34613284
Pancytopenia 34.30 34.14 47 3791 95110 34857983
Acute stress disorder 34.23 34.14 7 3831 170 34952923

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaemia 588.54 33.88 370 5193 444645 79294180
Rash 265.40 33.88 258 5305 578100 79160725
Thrombocytopenia 163.15 33.88 140 5423 265119 79473706
Pancytopenia 143.47 33.88 107 5456 165638 79573187
Anal pruritus 121.61 33.88 24 5539 777 79738048
Pruritus 106.62 33.88 134 5429 394514 79344311
Leukopenia 95.75 33.88 73 5490 116440 79622385
Dry skin 84.75 33.88 55 5508 67940 79670885
Aplastic anaemia 83.01 33.88 35 5528 17870 79720955
Depressed mood 72.42 33.88 44 5519 48436 79690389
Haemoglobin decreased 70.52 33.88 82 5481 222037 79516788
Anorectal discomfort 63.42 33.88 19 5544 3592 79735233
Influenza like illness 54.64 33.88 43 5520 71664 79667161
Drug reaction with eosinophilia and systemic symptoms 49.97 33.88 39 5524 64205 79674620
Neutropenia 49.63 33.88 79 5484 287631 79451194
Fatigue 47.43 33.88 157 5406 929570 78809255
Dermatitis 47.08 33.88 25 5538 21296 79717529
Skin irritation 45.60 33.88 20 5543 11220 79727605
Wrong dose 43.58 33.88 12 5551 1682 79737143
Retinopathy 41.49 33.88 14 5549 3877 79734948
Toxic skin eruption 40.56 33.88 23 5540 22270 79716555
Hepatitis C 38.20 33.88 18 5545 11907 79726918
Hepatic failure 36.79 33.88 32 5531 61180 79677645

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AP02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HCV infections
FDA MoA N0000182638 HCV NS3/4A Protease Inhibitors
FDA EPC N0000182639 Hepatitis C Virus NS3/4A Protease Inhibitor
FDA MoA N0000185503 P-Glycoprotein Inhibitors
FDA MoA N0000190107 Organic Anion Transporting Polypeptide 1B1 Inhibitors
FDA MoA N0000190109 Organic Anion Transporting Polypeptide 2B1 Inhibitors
FDA MoA N0000190114 Cytochrome P450 3A Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:63175 peptidomimetics
CHEBI has role CHEBI:64924 hepatitis C protease inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chronic hepatitis C indication 128302006
Anemia contraindication 271737000 DOID:2355




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.64 acidic
pKa2 13.65 acidic
pKa3 2.9 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
375MG INCIVEK VERTEX PHARMS N201917 May 23, 2011 DISCN TABLET ORAL 8431615 May 30, 2028 METHOD OF TREATING CHRONIC HEPATITIS C

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Neutrophil elastase Enzyme IC50 6.17 CHEMBL
Chymotrypsin-like elastase family member 1 Enzyme IC50 7.52 CHEMBL
Cathepsin B Enzyme IC50 6.68 CHEMBL
Cathepsin L1 Enzyme IC50 5.46 CHEMBL
Chymase Enzyme IC50 7.59 CHEMBL
Lysosomal protective protein Enzyme INHIBITOR IC50 7 IUPHAR
Cathepsin L2 Enzyme IC50 5.87 CHEMBL
Cathepsin K Enzyme IC50 6.20 CHEMBL
Cathepsin S Enzyme IC50 6.52 CHEMBL
Plasminogen Enzyme IC50 5.06 CHEMBL
Hepatitis C virus serine protease, NS3/NS4A Enzyme INHIBITOR CHEMBL CHEMBL
Replicase polyprotein 1ab Enzyme IC50 4.94 CHEMBL
NS3 protease Unclassified IC50 6.89 CHEMBL
NS3 protease Unclassified Ki 7.09 CHEMBL
NS3 protease Unclassified Ki 8.41 CHEMBL

External reference:

IDSource
4030729 VUID
N0000182739 NUI
D09012 KEGG_DRUG
4030729 VANDF
C1876229 UMLSCUI
CHEBI:68595 CHEBI
CHEMBL231813 ChEMBL_ID
DB05521 DRUGBANK_ID
C486464 MESH_SUPPLEMENTAL_RECORD_UI
7871 IUPHAR_LIGAND_ID
8686 INN_ID
655M5O3W0U UNII
3010818 PUBCHEM_CID
1102261 RXNORM
181488 MMSL
27888 MMSL
d07777 MMSL
013797 NDDF
698806003 SNOMEDCT_US
704466001 SNOMEDCT_US
SV6 PDB_CHEM_ID

Pharmaceutical products:

None